8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 14, 2005

HELIX BIOMEDIX, INC.

(Exact name of registrant as specified in its charter)

DELAWARE	033-20897-D	91-2099117
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(IRS Employer Identification No.)

22122 20^th Avenue S.E., Suite 148
Bothell, Washington 98021
(425) 402-8400

(Address and telephone number of registrant’s principal executive offices)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On December 16, 2005, Helix BioMedix, Inc. (the “Company”) announced that Richard M. Cohen has been appointed to the Company’s Board of Directors as a Class I Director and to the Audit Committee of the Company’s Board of Directors effective as of December 14, 2005. A copy of the press release announcing this appointment is being filed as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

     (d) Exhibits.

Exhibit No.	Description
99.1	Press release, dated December 16, 2005, issued by Helix BioMedix, Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	HELIX BIOMEDIX, INC.
Dated: December 16, 2005	By:	/s/ R. Stephen Beatty
		R. Stephen Beatty
		President and Chief Executive Officer

EX-99.1

EXHIBIT 99.1

HELIX BIOMEDIX ANNOUNCES APPOINTMENT OF RICHARD M. COHEN
TO ITS BOARD OF DIRECTORS

Bothell, Washington — December 16, 2005 — Helix BioMedix, Inc. (HXBM.OB) today announced that Richard M. Cohen has been appointed to its Board of Directors. The addition of Mr. Cohen increases the size of Helix BioMedix’s Board to eight. Mr. Cohen will also serve on the Company’s audit committee.

Mr. Cohen, age 54, is the Managing Principal of Richard M. Cohen Consultants, Inc. (RMCC), which was formed to enhance shareholder value for public and private company clients. He has more than two decades of diverse business experience, including serving as president and chief financial officer of several RMCC clients. Prior to forming RMCC in 1995, Mr. Cohen was President of General Media, Inc., a major international publishing and media company.

Mr. Cohen has an M.B.A. from Stanford University, a B.S. cum laude from the Wharton School of Business at the University of Pennsylvania and is a C.P.A. He is currently on the board of directors of Dune Energy, a publicly traded oil and gas exploration company, and Flaghouse Communications, a privately held marketer of physical education equipment.

R. Stephen Beatty, President and Chief Executive Officer of Helix BioMedix, commented, “We are very excited to have Richard Cohen join our Board. His financial expertise, Wall Street background and significant hands-on operating experience make Richard an excellent candidate. In addition, his diverse industry experience, including five years in consumer marketing with Revlon, will prove valuable as we move ahead with the commercialization of our proprietary peptides on the consumer product side.”

About Helix BioMedix

Helix BioMedix, Inc. is an early-stage biopharmaceutical company that has a portfolio of issued patents that covers six distinct classes of peptides, including over 1 million unique peptide sequences. The company’s mission is to become the industry leader in developing and commercializing small proteins known as bioactive peptides. The antimicrobial and wound healing properties of these peptides qualify them for inclusion in a wide range of both pharmaceutical and consumer products. The company is currently focused on the development of selected peptides as topical anti-infectives and in wound healing. Non-pharmaceutical applications being pursued by Helix BioMedix include adjuvants for cosmetics/cosmeceuticals, personal care, plant health, animal health and wide-spectrum biocides. More information about the company and its proprietary peptides can be found on the company’s website at www.helixbiomedix.com.

Important Notice

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, including activities, events or developments that the company expects, believes or anticipates will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company’s ability to successfully raise additional capital, enter into revenue generating license agreements, continue its research and development efforts, including pre-clinical and clinical studies, and general economic conditions. Additional assumptions, risks and uncertainties are described in detail in our reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at www.sec.gov. Readers are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.

Contact:
Helix BioMedix, Inc.	Investor Relations:
David H. Kirske, 425-402-8400	Cameron Associates
dkirske@helixbiomedix.com	Paul G. Henning, 212-554-5462
or:	paul@cameronassoc.com

###